The laboratory of Inflammation, Microbiome and Immunosurveillance, located in the Faculty of Pharmacy – Chatenay Malabry (UMR-996 INSERM – Paris-Saclay University) is composed of biologists combining expertise in the fields of Immunology, Virology, and Pathophysiology.


Our objectives are to analyze the pathological mechanisms of three classes of diseases: immune (autoimmunity and immunodeficiencies) and inflammatory related to chemical agents/drugs or metabolic liver disorders. The team has developed an expertise in the area of ADA measurement in the context of the ABIRISK IMI project. Marc Pallardy was the academic coordinator of this project. We currently dose ADA for infliximab and adalimumab and we are in the process of validating an ADA dosage for Nivolumab.

Diseases Researched:

The main research axis of the team « Drug and Chemical Allergy, Immunotoxicology and Immunopathology » is the understanding of the physiopathological mechanisms related to immunopathologies of allergic origin and in response to immunization’s adjuvants.

We have investigating ADA measurements in:

  • Rheumatoid Arthritis (RA)
  • Inflammatory Bowel Disease (IBD) like Crohn's symptoms
  • Cancer indications.

Performed Tests:

Photo: N/A

INSERM UMR 996, TEAM II, provide serivice for

  • Infliximab ADA
  • Adalimumab ADA
  • Under progress is Nivolumab ADA